Cochrane · systematic review · CD007571
Vedolizumab for induction and maintenance of remission in ulcerative colitis
Bickston, SJ, Behm, BW, Tsoulis, DJ, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 4 · 57.1%High 3 · 42.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Vedolizumab versus placebo for induction of remission in ulcerative colitis
Population: Patients with moderately to severely active ulcerative colitis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Failure to induce clinical remission Vedolizumab vs placebo | RR 0.86 [0.8, 0.91] | 4 studies · 606 participants | High |
Failure to induce clinical response Vedolizumab vs placebo | RR 0.68 [0.59, 0.78] | 3 studies · 601 participants | Moderate Downgraded: imprecision |
Failure to induce endoscopic remission Vedolizumab vs placebo | RR 0.82 [0.75, 0.91] | 3 studies · 583 participants | High |
Clinical relapse Vedolizumab vs placebo | RR 0.67 [0.59, 0.77] | 1 study · 373 participants | Moderate Downgraded: imprecision |
Endoscopic relapse Vedolizumab vs placebo | RR 0.58 [0.49, 0.68] | 1 study · 373 participants | Moderate Downgraded: imprecision |
Adverse events Vedolizumab vs placebo | RR 0.99 [0.93, 1.07] | 2 studies · 941 participants | High |
Serious adverse events Vedolizumab vs placebo | RR 1.01 [0.72, 1.42] | 3 studies · 1122 participants | Moderate Downgraded: imprecision |